NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it is scheduled to attend two investor conferences during the month of March 2022.
Oppenheimer 32nd Annual Virtual Healthcare Conference
|Date and time:||March 16, 2022, at 1:20 p.m. ET.|
|Format:||Presentation, 1-on-1 meetings|
34th Annual ROTH Conference
|Dates:||March 13-15, 2022|
|Location:||Ritz-Carlton, Laguna Niguel, California|
|Format:||1-on-1 meetings and select analyst fireside chats|
|Registration;||Contact your ROTH representative|
During the conferences, NeuroOne Chief Executive Officer Dave Rosa will discuss the Company’s high-definition, minimally invasive thin-film Evo® Cortical Electrodes for the diagnosis of various neurological conditions. Leveraging its game-changing technology developed in collaboration with Mayo Clinic, NeuroOne’s upcoming commercial and development catalysts include the Evo® sEEG diagnostic line (if cleared by the FDA) and further development of a combination diagnostic and ablation electrode system, as well as the potential for technology adaptation and entry into artificial intelligence and machine learning markets.
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.